PubMed Health⌕ Search

PubMed · 9567357

Bisphosphonates: structure-activity relations from a clinical perspective.

Abstract

Bisphosphonates, synthetic compounds containing two phosphonate groups bound to a central (geminal) carbon (P-C-P) and two additional chains (R1 and R2, respectively) bind strongly to calcium crystals, inhibit their growth and suppress osteoclast-mediated bone resorption. The availability of two side chains allows numerous substitutions and the development of a variety of analogs with different pharmacological properties. The R1 structure together with the P-C-P are primarily responsible for binding to bone mineral and for the physicochemical actions of the bisphosphonates and a hydroxyl group at R1 provides optimal conditions for these actions. The R2 is believed to be responsible for the antiresorptive action of the bisphosphonates and small modifications or conformational restrictions of this part of the molecule may result in marked differences in antiresorptive potency. The presence of a nitrogen function in an alkyl chain or in a ring structure in R2 greatly enhances the antiresorptive potency and specificity of bisphosphonates for bone resorption and most of the newer potent bisphosphonates contain a nitrogen in their structure. Recent evidence, however, suggests that the whole bisphosphonate molecule is essential for antiresorptive action. Thus, although the basic structural requirements for bisphosphonate actions have been defined, precise structure-activity relations have not been defined yet. These are essential for elucidating their molecular mechanism of action and for the rational design of compounds for various clinical indications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S E Papapoulos. 1997. Bisphosphonates: structure-activity relations from a clinical perspective.. https://pubmed.ncbi.nlm.nih.gov/9567357/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A new reconstructive technique for intercalary defects of long bones: the association of massive allograft with vascularized fibular autograft. Long-term results and comparison with alternative techniques.

In 1988, the excellent results obtained with the use of vascularized fibular autograft as a salvage procedure in massive allograft failures caused by non-union or massive resorption prompted a trial of an original reconstructive technique for intercalary defects based on the primary combination of the two types of graft. The authors believe the excellent final results and the ability to avoid further salvage surgical procedures justify the primary application of this more complicated technique despite longer surgical times.

Bone Resorption↗

FSH and bone--important physiology or not?

For many years, osteoporosis in women was equated with estrogen deficiency. The recent articles by Zaidi and colleagues offer a new challenge to the estrogen-deficiency-osteoporosis hypothesis by showing that follicle-stimulating hormone (FSH) stimulates osteoclastic bone resorption perhaps through tumor necrosis factor-alpha (TNF-alpha). These authors, however, neglected to mention bone abnormalities and high testosterone levels that were previously shown in FSH-receptor knockout and other modified mice. It is also possible that they have overemphasized potential relationships of these new data with human bone loss. Despite these fascinating data, the paradigm of FSH causing hypogonadal bone loss is not yet ready to displace the estrogen-deficiency-osteoporosis paradigm, although that model already faces considerable challenge.

Bone Resorption↗

Natural inhibitors targeting osteoclast-mediated bone resorption.

Human cathepsin K, matrix metalloproteinase 9, and alpha(V)beta(3) integrin are the key regulators in osteoclast-mediated bone resorption. In this paper, we found natural inhibitors 1-10 for them by enzyme inhibition assays. Inhibitors 1-7, 8-9, and 10 are novel inhibitors of human cathepsin K, matrix metalloproteinase 9, and alpha(V)beta(3), respectively.

Bone Resorption↗